Zanubrutinib for HLH

• Status: Recruiting
• Trial end date: 2023-04-01
• Target enrollment: 0
• Participant gender: All

Summary

This study is a prospective single-arm clinical study, focusing on Hemophagocytic lymphohistocytosis，to evaluate the clinical efficacy and safety of zanubrutinib.

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Beijing Friendship Hospital
• Treatments: Zanubrutinib

Criteria

Inclusion Criteria:

1. Unlimited gender, age ≥ 14 years old;

2. HLH was diagnosed according to HLH-04 diagnostic criteria;

3. Before the study, there was no severe liver function injury; Serum creatinine ≤ 1.5 times the upper limit of normal value;

4. Sign informed consent

Exclusion Criteria:

1. Allergic to zebutinib;

2. Currently active important cardiovascular diseases with clinical significance; The functions of important organs such as heart and lung unrelated to HLH were seriously abnormal;

3. Known human immunodeficiency virus (HIV) or active hepatitis B (HBV) or hepatitis C (HCV) infection;

4. Pregnant or lactating women and patients of childbearing age who refuse to take appropriate contraceptive measures during this trial;

5. Serious mental illness;

6. Active massive hemorrhage of internal organs;

7. Uncontrollable infection;

8. At the same time, participate in other clinical researchers